ReviewHandbook of experimental pharmacology2009
Viral protease inhibitors.
Review in Handbook of experimental pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 133 citations in OpenAlex.
- Activated Sludge in the Bioremediation of Water Containing SARS-CoV-2 Antivirals.Journal of xenobiotics · 2026Article
- Article
- High-Throughput Activity Reprogramming of Proteases (HARP).ACS chemical biology · 2025Article
- Brief communication: The extent and determinants of viral suppression among patients on protease inhibitor-based Anti-retro-viral therapy undergoing intensive adherence counselling in a public HIV care center in Uganda.AIDS research and therapy · 2024Article
- The Role of Peptides in Combatting HIV Infection: Applications and Insights.Molecules (Basel, Switzerland) · 2024Review
- InBiochemistry and biophysics reports · 2024Article
- Utilizing sinapic acid as an inhibitory antiviral agent against MERS-CoV PLpro.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- A Non-Active-Site Inhibitor with Selectivity for Zika Virus NS2B-NS3 Protease.ACS infectious diseases · 2024Article
- Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?Molecular therapy. Nucleic acids · 2023Article
- Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.Science advances · 2023Article
- Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.bioRxiv : the preprint server for biology · 2022Article
- Proteolytic Processing of the Coronavirus Replicase Nonstructural Protein 14 Exonuclease Is Not Required for Virus Replication but Alters RNA Synthesis and Viral Fitness.Journal of virology · 2022Article
- Investigation of Cu metal nanoparticles with different morphologies to inhibit SARS-CoV-2 main protease and spike glycoprotein using Molecular Docking and Dynamics Simulation.Journal of molecular structure · 2022Article
- Drugs to limit Zika virus infection and implication for maternal-fetal health.Frontiers in virology (Lausanne, Switzerland) · 2022Article
- An Overview of Antiviral Peptides and Rational Biodesign Considerations.Biodesign research · 2022Review
- Human herpesvirus-encoded MicroRNA in host-pathogen interaction.Advances in biological regulation · 2021Review
- The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation.PLoS pathogens · 2021Article
- Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.Journal of clinical medicine · 2021Review
- The proximal proteome of 17 SARS-CoV-2 proteins links to disrupted antiviral signaling and host translation.bioRxiv : the preprint server for biology · 2021Article
- Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease.Chemical science · 2021Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
This review provides an overview of the development of viral protease inhibitors as antiviral drugs. We concentrate on HIV-1 protease inhibitors, as these have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of a potent protease inhibitor for other viruses if the processing site sequence and the catalytic mechanism are known. At this time, interest in developing inhibitors is limited to viruses that cause chronic disease, viruses that have the potential to cause large-scale epidemics, or viruses that are sufficiently ubiquitous that treating an acute infection would be beneficial even if the infection was ultimately self-limiting. Protease inhibitor development is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovirus, rhinovirus, and coronavirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.